Eli Lilly raised its full-year profit and revenue forecast on Tuesday after demand for its weight-loss treatment Zepbound and type 2 diabetes drug Mounjaro surged, sending its shares up about 8% premarket. Sky-rocketing demand for Mounjaro and Zepbound, both chemically known as tirzepatide, has…
#elililly #tesla #walmart #lilly #mounjaro #zepbound #danish #novonordisk #indianapolis
Continue reading...